Rocket Pharmaceuticals Releases Preclinical Data for First Investigational Gene Therapy Program for Rare Heart Disorder

Rocket Pharmaceuticals Releases Preclinical Data for First Investigational Gene Therapy Program for Rare Heart Disorder

Source: 
CP Wire
snippet: 
  • Danon disease has an estimated prevalence of about 15,000-30,000 patients in the U.S. and E.U.
  • Danon disease is a devastating multisystemic disorder that typically leads to death in patients from progressive heart failure in their teens and twenties
  • RP-A501 elicited phenotypic reversals at a structural and molecular level in cardiac, liver, and skeletal muscle tissue